Biographical summary
Mark D. Tyson II, M.D., is a urologic oncologist, with subspecialty interest in bladder cancer. His clinical focus includes:
- Treatments for muscle invasive and nonmuscle invasive bladder cancer.
- Robotic and open cystectomy
- Ileal conduits and orthotopic neobladders
- Intravesical therapy for nonmuscle invasive bladder cancer
- Understanding and improving quality of life for patients with bladder cancer
- Blue light cystoscopy, including in-office flexible blue light.
In addition to his clinical activities, Dr. Tyson is active in research and education, providing mentorship to trainees. He authors expert content and publishes regularly in scientific journals. He is currently recruiting patients for multiple clinical trials for patients with bladder cancer:
- SWOG S1602: A phase III randomized trial to evaluate the influence of BCG strain differences and T-cell priming with intradermal BCG before intravesical therapy for BCG-naive high-grade non-muscle invasive bladder cancer.
- TAR-200-103: A multicenter study evaluating safety and efficacy of TAR-200 in subjects with muscle-invasive urothelial carcinoma of the bladder who are ineligible for or refuse cisplatin-based chemotherapy and who are unfit for radical cystectomy.
- UGN-101: A phase III multicenter trial evaluating the efficacy and safety of MitoGel on ablation of upper urinary tract urothelial carcinoma.
- UGN-102: A phase IIb, single-arm, multicenter trial to evaluate the efficacy and safety of UGN-102 as a chemoablation agent in patients with low grade non-muscle invasive bladder cancer at intermediate risk of recurrence.
- KEYNOTE-676: A phase III, randomized comparator-controlled clinical trial to study the efficacy and safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer that is persistent or recurrent following BCG induction.
- ALLIANCE A031803: A phase II trial of intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
Dr. Tyson also provides second opinions remotely for newly diagnosed bladder, testis, kidney and prostate cancers. To schedule a video visit, please call 480-342-3868.
Conditions treated
Procedures performed
Interests
- Urothelial carcinoma — bladder cancer and upper tract cancer
- Renal cell carcinoma
- Prostate cancer
- Testis cancer
Mayo Clinic locations
Education
-
MPH - Epidemiology and BiostatisticsHarvard T. H. Chan School of Public Health
-
Fellow - Urologic OncologyDepartment of Urologic Surgery, Vanderbilt University School of Medicine
-
ResidentUrology Residency, Urology, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
-
ResidentSurgery - Preliminary Residency, Surgery, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
-
MD - HonorsDartmouth Medical School
-
BS - Molecular and Cellular Biology, HonorsUniversity of Arizona
Activities and honors
Awards and honors
- 2019
Educator of the Year Award (Research)Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Department of Education Administration
- 2018
Kern Scholar, Science of Health Care Delivery Mayo Clinic
- 2018
Christian Haub Family Career Development Award in Cancer ResearchMayo Clinic
- 2017
Best Paper, Resident CornerEuropean Urology
- 2017
Best ReviewerThe Journal of Urology
- 2013
1st Prize, Health Policy Resident Essay ContestWSAUA
- 2009
Alpha Omega AlphaAlpha Omega Alpha Honor Medical Society
- 2006
Magna Cum LaudeUniversity of Arizona
Professional memberships
- 2020 - present
MemberInstitutional Review Board - Wednesday - Mayo Clinic, Institutional Review Board, Mayo Clinic Committees
- 2018 - present
MemberPatient Safety Incident Review Group - AZ, Patient Safety Subcommittee, Continuous Improvement Committee
- 2018 - present
ChairSurgical Quality Subcommittee, Surgical and Procedural Committee, Clinical Practice Committee - Arizona
- 2018 - present
MemberInfection Prevention and Control Subcommittee, Clinical Practice Committee - Arizona, Executive Operations Team - Arizona
- 2018 - present
ChampionSurgical Champion for Mayo Clinic in Arizona, National Surgical Quality Improvement Program, American College of Surgeons
- 2017 - present
MemberBladder Cancer Think Tank, Bladder Cancer Advocacy Network
- 2017 - present
MemberGenitourinary Disease Oriented Group (GU DOG), Department of Urology
- 2017 - present
MemberLower Genitourinary Disease Oriented Group (DOG), Mayo Clinic Task Forces/Work Groups
- 2017 - present
MemberSurgical Quality Subcommittee, Surgical and Procedural Committee, Clinical Practice Committee - Arizona
- 2017 - present
MemberClinical Competency Committee, Urology Residency - Arizona, Mayo Clinic School of Graduate Medical Education
- 2015 - present
MemberSociety of Urologic Oncology
- 2015 - present
MemberVanderbilt Urological Society
- 2010 - present
MemberAmerican Urological Association
- 2010 - present
MemberWestern Section American Urological Association
- 2010 - present
MemberArizona Urological Society
- 2010 - present
MemberPhoenix Urologic Society
Publications